Matches in SemOpenAlex for { <https://semopenalex.org/work/W2183615775> ?p ?o ?g. }
- W2183615775 abstract "Purpose: This phase II study evaluated weekly trastuzumab and paclitaxel therapy in women with HER2normal and HER2-overexpressing metastatic breast cancer. Efficacy was correlated with immunohistochemical and fluorescent in situ hybridization (FISH) assay results. Patients and Methods: Eligible patients had bidimensionally measurable metastatic breast cancer. Up to three prior chemotherapy regimens, including prior anthracycline and taxane therapy, were allowed. Trastuzumab 4 mg/kg and paclitaxel 90 mg/m 2 were administered on week 1, with trastuzumab 2 mg/kg and paclitaxel 90 mg/m 2 administered on subsequent weeks. HER2 status was evaluated using four different immunohistochemical assays and FISH. Results: Patients received a median of 25 weekly infusions (range, one to 85 infusions). Median delivered paclitaxel dose-intensity was 82 mg/m 2 /wk (range, 52 to 90 mg/m 2 /wk). The intent-to-treat response rate for all 95 patients enrolled was 56.8% (95% confidence interval, 47% to 67%). A response rate of 61.4% (4.5% complete response, 56.8% partial response) was observed in 88 fully assessable patients. In patients with HER2-overexpressing tumors, overall response rates ranged from 67% to 81% compared with 41% to 46% in patients with HER2-normal expression (ranges reflect the different assay methods used to assess HER2 status). Differences in response rates between patients with HER2-overexpressing tumors and those with normal HER2 expression were statistically significant for all assay methods, with CB11 and TAB250 antibodies and FISH having the strongest significance. Therapy was generally well tolerated, although three patients had serious cardiac complications. Conclusion: Weekly trastuzumab and paclitaxel therapy is active in women with metastatic breast cancer. Therapy was relatively well tolerated; however, attention to cardiac function is necessary. J Clin Oncol 19:2587-2595. © 2001 by American Society of Clinical Oncology." @default.
- W2183615775 created "2016-06-24" @default.
- W2183615775 creator A5002194858 @default.
- W2183615775 creator A5002412540 @default.
- W2183615775 creator A5002965160 @default.
- W2183615775 creator A5003740335 @default.
- W2183615775 creator A5006839105 @default.
- W2183615775 creator A5009811727 @default.
- W2183615775 creator A5011528560 @default.
- W2183615775 creator A5011803946 @default.
- W2183615775 creator A5018617106 @default.
- W2183615775 creator A5020083811 @default.
- W2183615775 creator A5024919184 @default.
- W2183615775 creator A5032987754 @default.
- W2183615775 creator A5039225060 @default.
- W2183615775 creator A5047713528 @default.
- W2183615775 creator A5053200909 @default.
- W2183615775 creator A5069795948 @default.
- W2183615775 creator A5072442772 @default.
- W2183615775 creator A5076780750 @default.
- W2183615775 creator A5080832682 @default.
- W2183615775 creator A5082865186 @default.
- W2183615775 creator A5087724207 @default.
- W2183615775 date "2001-01-01" @default.
- W2183615775 modified "2023-09-27" @default.
- W2183615775 title "Weekly T rastuzumab a nd P aclitaxel T herapy f or M etastatic Breast C ancer W ith A nalysis o f E fficacy b y HER2 Immunophenotype a nd G ene A mplification" @default.
- W2183615775 cites W129955880 @default.
- W2183615775 cites W1583886175 @default.
- W2183615775 cites W1755920412 @default.
- W2183615775 cites W1910168157 @default.
- W2183615775 cites W1933350662 @default.
- W2183615775 cites W1946819517 @default.
- W2183615775 cites W1955757631 @default.
- W2183615775 cites W1984274637 @default.
- W2183615775 cites W2000837172 @default.
- W2183615775 cites W2001627828 @default.
- W2183615775 cites W2019895529 @default.
- W2183615775 cites W2024122808 @default.
- W2183615775 cites W2030273692 @default.
- W2183615775 cites W2043711125 @default.
- W2183615775 cites W2060531515 @default.
- W2183615775 cites W2076440683 @default.
- W2183615775 cites W2094627540 @default.
- W2183615775 cites W2095156669 @default.
- W2183615775 cites W2104528117 @default.
- W2183615775 cites W2110442763 @default.
- W2183615775 cites W2138692412 @default.
- W2183615775 cites W2141393790 @default.
- W2183615775 cites W2154027407 @default.
- W2183615775 cites W2156544288 @default.
- W2183615775 cites W2159363679 @default.
- W2183615775 cites W2159459001 @default.
- W2183615775 cites W2165528796 @default.
- W2183615775 cites W2169577449 @default.
- W2183615775 cites W2222638000 @default.
- W2183615775 cites W2287205592 @default.
- W2183615775 cites W2344444710 @default.
- W2183615775 cites W2346544306 @default.
- W2183615775 cites W2418327139 @default.
- W2183615775 hasPublicationYear "2001" @default.
- W2183615775 type Work @default.
- W2183615775 sameAs 2183615775 @default.
- W2183615775 citedByCount "0" @default.
- W2183615775 crossrefType "journal-article" @default.
- W2183615775 hasAuthorship W2183615775A5002194858 @default.
- W2183615775 hasAuthorship W2183615775A5002412540 @default.
- W2183615775 hasAuthorship W2183615775A5002965160 @default.
- W2183615775 hasAuthorship W2183615775A5003740335 @default.
- W2183615775 hasAuthorship W2183615775A5006839105 @default.
- W2183615775 hasAuthorship W2183615775A5009811727 @default.
- W2183615775 hasAuthorship W2183615775A5011528560 @default.
- W2183615775 hasAuthorship W2183615775A5011803946 @default.
- W2183615775 hasAuthorship W2183615775A5018617106 @default.
- W2183615775 hasAuthorship W2183615775A5020083811 @default.
- W2183615775 hasAuthorship W2183615775A5024919184 @default.
- W2183615775 hasAuthorship W2183615775A5032987754 @default.
- W2183615775 hasAuthorship W2183615775A5039225060 @default.
- W2183615775 hasAuthorship W2183615775A5047713528 @default.
- W2183615775 hasAuthorship W2183615775A5053200909 @default.
- W2183615775 hasAuthorship W2183615775A5069795948 @default.
- W2183615775 hasAuthorship W2183615775A5072442772 @default.
- W2183615775 hasAuthorship W2183615775A5076780750 @default.
- W2183615775 hasAuthorship W2183615775A5080832682 @default.
- W2183615775 hasAuthorship W2183615775A5082865186 @default.
- W2183615775 hasAuthorship W2183615775A5087724207 @default.
- W2183615775 hasConcept C121608353 @default.
- W2183615775 hasConcept C126322002 @default.
- W2183615775 hasConcept C204232928 @default.
- W2183615775 hasConcept C2775930923 @default.
- W2183615775 hasConcept C2776694085 @default.
- W2183615775 hasConcept C2776802502 @default.
- W2183615775 hasConcept C2777292972 @default.
- W2183615775 hasConcept C2777511904 @default.
- W2183615775 hasConcept C2779786085 @default.
- W2183615775 hasConcept C44249647 @default.
- W2183615775 hasConcept C530470458 @default.
- W2183615775 hasConcept C71924100 @default.
- W2183615775 hasConcept C90924648 @default.
- W2183615775 hasConceptScore W2183615775C121608353 @default.
- W2183615775 hasConceptScore W2183615775C126322002 @default.